UNSPSC 51121918: Draflazine

This classification denotes a cardiotonic agent and antiplatelet agent with the molecular formula C30H33Cl2F2N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y25DT968Y, chemically known as 1-piperazineacetamide, 2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-,(+-)- but generally known as draflazine, which bears US NIH Compound Identifier 60849. European Medicines Agency schedules Draflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06395MIG.

UNSPSC 51121918 Draflazine, a Commodity code, covers emergency and acute-care pharmaceutical supplies that state and local governments procure for fire rescue services, public health agencies, and cooperative purchasing consortia. Recent solicitations show state and local buyers acquiring specific injectable medications—epinephrine, labetalol, adenosine, and diltiazem formulations—used in advanced life support protocols, as well as broader generic pharmaceutical and over-the-counter product lines distributed through authorized drug wholesalers to support multi-jurisdictional public health and emergency response networks. The issuing bodies include city purchasing departments (fire rescue logistics), state health and human services commissions (pharmacy benefit and prescription fulfillment programs), and regional cooperative purchasing alliances serving multiple states. Fire rescue agencies and state Medicaid or employee health programs dominate the recent activity, with cooperative purchasing vehicles extending reach across multiple state and local jurisdictions.

Geographic activity spans Florida, Texas, and Minnesota, with cooperative purchasing extending into Oregon. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, specifying 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a one-year contract term and optional two-year renewals; the estimated contract value is $40,000. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities for direct-to-manufacturer pharmacy benefit programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson; the RFP requires vendors to maintain comprehensive insurance, cGMP certification, and DSCSA compliance, with contract effectiveness set for July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation.